Carlsmed (CARL) Cash from Financing Activities (2024 - 2026)

Carlsmed has reported Cash from Financing Activities for 3 years, with the latest figure at $436000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 96.27% year-over-year to $436000.0; the trailing twelve-month figure through Mar 2026 stood at $88.9 million (changed N/A YoY), and the FY2025 full-year result was $100.1 million, up 71.16% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $436000.0, up from -$29000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $90.7 million in Q3 2025, with the low at -$2.2 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $16.3 million across 3 years, with a median of $436000.0 in 2026.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities soared 551.41% — and 2026, when it slumped 96.27%.
• Carlsmed's Cash from Financing Activities stood at -$51000.0 in 2024, then jumped by 43.14% to -$29000.0 in 2025, then surged by 1603.45% to $436000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $436000.0 (Q1 2026), -$29000.0 (Q4 2025), and $90.7 million (Q3 2025), per Business Quant data.